NovaBridge Biosciences (NBP) Total Non-Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Total Non-Current Liabilities for 7 consecutive years, with $29.1 million the latest figure, recorded in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 152.34% year-over-year to $29.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.1 million (up 152.34% YoY) and the FY2025 annual result came in at $29.1 million, up 152.34% from the prior year.
• Total Non-Current Liabilities improved to $29.1 million in Q4 2025 per NBP's latest filing, from $11.5 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for NBP reached as high as $145.0 million in Q2 2023 and fell as low as $11.5 million in Q4 2024.
• A 5-year average of $54.3 million and a median of $33.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 1572.79% — and 2024, when it plunged 76.29%.
• Year by year, Total Non-Current Liabilities stood at $27.6 million in 2021, then climbed by 18.25% to $32.6 million in 2022, then surged by 48.89% to $48.6 million in 2023, then tumbled by 76.29% to $11.5 million in 2024, then surged by 152.34% to $29.1 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $29.1 million, $11.5 million, and $48.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.